前收市價 | 13.30 |
開市 | 13.00 |
買盤 | 0.00 |
賣出價 | 0.00 |
拍板 | 1,030.00 |
到期日 | 2024-06-21 |
今日波幅 | 12.10 - 14.00 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
Regeneron stock joined the 1,000-club this month as enthusiasm grows for its blockbuster drug, Dupixent, in COPD treatment.
The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.